Request Demo
Last update 06 Dec 2025
MSB-0254
Last update 06 Dec 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms MSB 0254 |
Target |
Action antagonists |
Mechanism VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with MSB-0254NCT04381325
Phase I Clinical Trial to Evaluate the Safety and Tolerability and Pharmacokinetics of MSB0254 Injection in Patients With Advanced Solid Tumors
100 Clinical Results associated with MSB-0254
Login to view more data
100 Translational Medicine associated with MSB-0254
Login to view more data
100 Patents (Medical) associated with MSB-0254
Login to view more data
100 Deals associated with MSB-0254
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Apr 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 22 | fsehzwzirm(dbbfczavqg) = One DLT was reported in 12mg/kg Q2W dose cohort. A subject with intra-cholangial carcinoma developed G3 (grade 3) upper gastrointestinal hemorrhage on the C1D13. The adverse event was resolved after symptomatic treatment. cqhmwcyjmx (jzzzojsdwa ) View more | Positive | 02 Jun 2022 | |||
Phase 1 | 19 | lmwrrifsid(leifbktpxf) = 高血压 6例（31.6%），中性粒细胞计数降低、γ-谷氨酰转移酶升高 和天门冬氨酸氨基转移酶升高各4例（21.1%），白细胞计数 降低、血小板计数降低、蛋白尿和贫血各3例（15.8%），上 消化道出血、牙龈出血和血尿症各2例（10.5%） qucmpobcxp (yuimuhkuzw ) View more | Positive | 25 Sep 2021 | |||
Phase 1 | 16 | jhurwdehes(letfrzxcyv) = yxljbzsevr demyvalhpn (twjihtjbso ) | - | 25 Sep 2021 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free